Iron Status in BTM With Blood Transfusion
Hematological and Biochemical Markers of Iron Status in Thalassemic Children Receiving Multiple Blood Transfusion
1 other identifier
observational
100
0 countries
N/A
Brief Summary
To assess the possible role of iron overload as a cause of liver dysfunction in thalassemic childrens receiving multiple blood transfusion and its correlation with serum aminotransferases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2021
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 24, 2021
CompletedFirst Posted
Study publicly available on registry
July 1, 2021
CompletedStudy Start
First participant enrolled
July 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2023
CompletedJuly 19, 2021
June 1, 2021
1 year
June 24, 2021
July 13, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Hematological and biochemical markers of Iron status in thalassemic children receiving multiple blood transfusion
Assessment the possible role of iron overload as a cause of liver dysfunction in thalassemic childrens receiving multiple blood transfusion and its correlation with serum aminotransferases.
baseline
Eligibility Criteria
all cases diagnosed as thalassemia major attending to thalassemic center at hematological department at Assuit university childern hospital.
You may qualify if:
- Thalassemic patients of both sex.
- Beta-thalassemia major patients diagnosed Clinical and laboratory .
- Age 5 : 18 years.
- Undergoing multiple blood transfusion.
You may not qualify if:
- Age less than 5 years.
- Acute illness as fever and infections.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (3)
Al-Moshary M, Imtiaz N, Al-Mussaed E, Khan A, Ahmad S, Albqami S. Clinical and Biochemical Assessment of Liver Function Test and Its Correlation with Serum Ferritin Levels in Transfusion-dependent Thalassemia Patients. Cureus. 2020 Apr 7;12(4):e7574. doi: 10.7759/cureus.7574.
PMID: 32391223BACKGROUNDAmjad F, Fatima T, Fayyaz T, Khan MA, Qadeer MI. Novel genetic therapeutic approaches for modulating the severity of beta-thalassemia (Review). Biomed Rep. 2020 Nov;13(5):48. doi: 10.3892/br.2020.1355. Epub 2020 Sep 2.
PMID: 32953110BACKGROUNDSalama KM, Ibrahim OM, Kaddah AM, Boseila S, Ismail LA, Hamid MM. Liver Enzymes in Children with beta-Thalassemia Major: Correlation with Iron Overload and Viral Hepatitis. Open Access Maced J Med Sci. 2015 Jun 15;3(2):287-92. doi: 10.3889/oamjms.2015.059. Epub 2015 May 28.
PMID: 27275237BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Mohamed M Ghazally, professor
Egypt
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principle investigator
Study Record Dates
First Submitted
June 24, 2021
First Posted
July 1, 2021
Study Start
July 1, 2021
Primary Completion
July 1, 2022
Study Completion
March 1, 2023
Last Updated
July 19, 2021
Record last verified: 2021-06